Natera (NTRA) to Release Quarterly Earnings on Thursday

Natera (NASDAQ:NTRA) is expected to post its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $514.5510 million for the quarter. Natera has set its FY 2025 guidance at EPS.Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The business had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business’s quarterly revenue was up 32.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.30) EPS. On average, analysts expect Natera to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Natera Trading Down 0.9%

NASDAQ:NTRA traded down $1.78 during trading hours on Tuesday, reaching $196.45. 1,848,895 shares of the company traded hands, compared to its average volume of 1,417,125. The business’s 50-day moving average price is $175.16 and its two-hundred day moving average price is $162.43. Natera has a 1 year low of $122.08 and a 1 year high of $203.23. The stock has a market capitalization of $26.96 billion, a P/E ratio of -102.85 and a beta of 1.74.

Insider Activity

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $159.99, for a total value of $479,970.00. Following the sale, the insider directly owned 117,559 shares in the company, valued at approximately $18,808,264.41. This trade represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Rowan E. Chapman sold 2,750 shares of the stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $166.99, for a total transaction of $459,222.50. Following the completion of the transaction, the director owned 6,015 shares of the company’s stock, valued at $1,004,444.85. This represents a 31.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 221,767 shares of company stock valued at $42,612,020 over the last ninety days. 5.63% of the stock is owned by company insiders.

Hedge Funds Weigh In On Natera

Several institutional investors and hedge funds have recently bought and sold shares of NTRA. Integrated Wealth Concepts LLC boosted its holdings in Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after purchasing an additional 96 shares in the last quarter. NewEdge Advisors LLC lifted its position in Natera by 68.3% in the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after purchasing an additional 1,847 shares during the period. Focus Partners Wealth increased its stake in Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after acquiring an additional 474 shares during the period. Sivia Capital Partners LLC acquired a new stake in Natera during the second quarter valued at approximately $298,000. Finally, WINTON GROUP Ltd bought a new position in shares of Natera during the 2nd quarter worth approximately $558,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on NTRA. Morgan Stanley reiterated an “overweight” rating and issued a $195.00 price target on shares of Natera in a research note on Sunday, August 10th. Evercore ISI raised shares of Natera to a “strong-buy” rating and set a $170.00 target price on the stock in a research report on Monday, July 28th. Canaccord Genuity Group restated a “buy” rating and set a $200.00 price objective on shares of Natera in a research note on Tuesday, October 14th. Cowen reaffirmed a “buy” rating on shares of Natera in a report on Friday, August 8th. Finally, Barclays restated an “overweight” rating and issued a $210.00 price objective (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $194.89.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.